AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 7 - (NewsRx.com & NewsRx.net) --
by Sonia Nichols, staff medical writer -- The properties of CD55, a cell membrane protein that neutralizes complement activation, make it a good candidate for immunotherapy targeting.
Laboratory analysis has recently shown that an antigen called 791Tgp72 is actually CD55, according to scientists at the University of Nottingham, U.K. This antigen has been used for imaging studies and therapies directed towards cancer cells. L. Li and colleagues propose that cells expressing this protein could be used for targeted drug therapies.
Li et al. compared the expression of CD55 in normal cells with expression in tumor cells ("CD55 is over-expressed in the tumor environment," British Journal of Cancer, 2001;84(1):80-86).
"Tumor cells showed a four- to 100-fold increase in CD55 cell surface expression when compared to normal cells," Li's group said.
When colorectal tumors were examined, CD55 was highly expressed in the stromal areas of those tumors, the researchers said. Further analysis of tumor cells grown in culture led investigators to observe deposition of CD55 into adjacent extracellular matrices, where they found that the quantity of extracellular deposition was directly proportional to ...
Source: HighBeam Research, Protein Up-Regulated By VEGF Is Suitable Target.(for immunotherapy)